IL18 and cancer: In addition, Xu et al. showed that the low expression of the METTL3/IL-18 axis in cancer-associated fibroblasts promotes PD-L1 expression in NSCLC cells, thus inhibiting the immune activity of CD8+T and aggravating the PD-L1 mediated immunosuppression of NSCLC [54].